New York City, NY -- (SBWIRE) -- 12/04/2013 -- StockMarketIntel.com issues a special report on the following stocks: Federal National Mortgage Association (OTCBB:FNMA), Affymax, Inc. (OTCMKTS:AFFY), Chromadex Corp (OTCMKTS:CDXC), Deutsche Telekom AG (ADR) (OTCMKTS:DTEGY)
Federal National Mortgage Association (OTCBB:FNMA) declined -2.84%, trading on 10.69 million shares, to end the trade at $2.74. The stock changed hands in a range of $2.73 to $2.89, bringing its market capitalization to about $3.17 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.25 and was moved to the maximum level of $5.44. Federal National Mortgage Association (Fannie Mae) provides liquidity and stability support services in the secondary mortgage market in the United States. The company securitizes mortgage loans originated by lenders in the primary mortgage market into Fannie Mae mortgage-backed securities (Fannie Mae MBS).
Has FNMA Found The Bottom And Ready To Gain Momentum? Find Out Here
Affymax, Inc. (OTCMKTS:AFFY) added 0.12%, to complete the trading session at $0.870, with a total volume of 164,957 shares. The stock, on average, trades on a volume of 368,130 shares. It floated in a range of $0.84 to $0.88 during the last trading session, with a beta value of 1.37. Its market capitalization now moved to about $32.62 million. In the past 52 weeks, the share price has not declined below $0.78 and above $27.71. Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses. It offers OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells.
Why Should Investors Buy AFFY After The Recent Gain? Just Go Here and Find Out
Chromadex Corp (OTCMKTS:CDXC) added 1.00%, to complete the trading session at $1.01, with a total volume of 84,945 shares. The stock, on average, trades on a volume of 219,336 shares. It floated in a range of $0.99 to $1.01 during the last trading session, with a beta value of -0.01. Its market capitalization now moved to about $105.90million. In the past 52 weeks, the share price has not declined below $0.50 and above $1.24. ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes proprietary-based ingredient technologies. The company utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. It provides seamless science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries.
What was the Moving Force behind CDXC on Bullish Run? Read This Research Report
Deutsche Telekom AG (ADR) (OTCMKTS:DTEGY) declined -1.34% yesterday, bringing its market capitalization around $68.91 billion. The share price, after opening at $15.47, made a high of $15.56 and hovered above $15.42 to end the day at $15.49. The total number of shares that changed hands during the session was 335,854 shares, as compared to average trading volume of 328,887 shares. Deutsche Telekom AG operates as an integrated telecommunication company worldwide. The company offers fixed-network services, such as voice and data communication services based on fixed-network and broadband technology; and sells terminal equipment and other hardware, as well as services to resellers.
Why Should Investors Buy DTEGY After the Recent Fall? Just Go Here and Find Out
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)